잠시만 기다려 주세요. 로딩중입니다.

Therapeutic New Era for Atopic Dermatitis: Part 2. Small Molecules

Annals of Dermatology 2021년 33권 2호 p.101 ~ 107
안지영, 최유성, Simpson Eric Lawrence,
소속 상세정보
안지영 ( Ahn Ji-Young ) - National Medical Center Department of Dermatology
최유성 ( Choi Yu-Sung ) - University of Ulsan College of Medicine Ulsan University Hospital Department of Dermatology
 ( Simpson Eric Lawrence ) - Oregon Health and Science University Department of Dermatology

Abstract


Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease driven by immune dysregulation and skin barrier dysfunction. Currently, we are experiencing a new era of understanding of the pathogenesis of AD and, as a consequence, a new era of innovation in therapeutics, including small molecules and biologic therapy. In contrast to biologics, small molecules are similar to conventional pharmacologic chemical agents used as drugs and are generally prepared by chemical synthesis. Unlike biologics, these drugs often are taken orally or formulated for topical use. The purpose of this review is to summarize the efficacy and safety of the current topical and systemic new therapies in AD by reviewing recently published papers on therapies currently in phase 2 or 3 clinical trials. In this review, it is important to note the characteristics of the study population, the primary endpoints, and whether or not there was concomitant topical therapy allowed. These study design elements may significantly alter the results of studies and should be taken into account. Targeted therapy help push AD treatment into a new era of personalized medicine.

키워드

Atopic dermatitis; New era; Small molecules; Therapeutics

원문 및 링크아웃 정보

 

등재저널 정보